Contemporary Applications and Limitations of Magnetic Resonance Imaging Contrast Materials

Journal of Urology

Volumn 183, Issue 1, 2010, Pages 27-33

  Natalin, Ricardo A ^a   Prince, Martin R ^a,c   Grossman, Marc E ^b   Silvers, David ^b   Landman, Jaime ^a  

^a Columbia University School of Medicine ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

chronic; gadolinium; kidney failure; magnetic resonance imaging; nephrogenic fibrosing dermopathy

Indexed keywords

CD34 ANTIGEN; COLLAGEN TYPE 1; CORTICOSTEROID; ECHOVIST; FIBRONECTIN; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMATINIB; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHOXSALEN; PROCOLLAGEN;

ANAMNESIS; ANTIGEN EXPRESSION; CELL ACTIVATION; CELL MIGRATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONSENSUS; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; EOSINOPHILIC FASCIITIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MACROPHAGE; MAGNETIC RESONANCE ANGIOGRAPHY; MOLECULAR MECHANICS; MORPHEA; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHAGOCYTOSIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PUVA; REVIEW; RISK FACTOR; SCLERODERMA; SCLEROMYXEDEMA; SKIN BIOPSY; SKIN FIBROBLAST; SKIN MANIFESTATION; SPINDLE CELL; TISSUE INTERACTION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; VENOUS STASIS;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; UROLOGIC DISEASES;

EID: 71249102934     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.09.029     Document Type: Review

References (46)

1. Dussol B., Morange S., Loundoun A., et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 21 (2006) 2120
2. Reed P.S., Dixon S.R., Boura J.A., et al. Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. Am J Cardiol 100 (2007) 1090
3. Cowper S.E., Robin H.S., Steinberg S.M., et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (2000) 1000
4. Grobner T. Gadolinium. A specific trigger for the development of nephrogenic systemic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104
5. Penfield J.G., and Reilly R.F. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?. Semin Dial 21 (2008) 129
6. Bussi S., Fouillet X., and Morisetti A. Toxicological assessment of gadolinium release from contrast media. Exp Toxicol Pathol 58 (2007) 323
7. Lucas R.L., Benjamin M., and Reineke T.M. Comparison of a tartaric acid derived polymeric MRI contrast agent to a small molecule model chelate. Bioconjug Chem 19 (2008) 24
8. Gibby W.A., Gibby K.A., and Gibby W.A. Comparison of Gd DTPA-BMA (Omniscan) versus Gd-Hp-DO3A (ProHance) retention in human bone tissue by inductive coupled plasma atomic emission spectroscopy. Invest Radiol 39 (2004) 138
9. Idee J.M., Port M., Raynal I., et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20 (2006) 563
10. Reilly R.F. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 3 (2008) 747
11. Brown J.J., Hynes M.R., and Wible Jr. J.H. Measurement of serum calcium concentration after administration of four gadolinium-based contrast agents to human volunteers. AJR Am J Roentgenol 189 (2007) 1539
12. Rodby R.A. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial 21 (2008) 145
13. Cowper S.E., Su L.D., Bhawan J., et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 (2001) 383
14. Ting W.W., Stone M.S., Madison K.C., et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139 (2003) 903
15. Cowper S.E. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website] (2001-2007). http://www.icnfdr.org Accessed April 8, 2008.
16. Cowper SE: Nephrogenic systemic fibrosis: an update. Presented at 2nd Annual Scientific Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-Containing Contrast Agents, New Haven, Connecticut, May 10, 2008.
17. Saab G., and Abu-Alfa A. Nephrogenic systemic fibrosis-Implications for nephrologists. Eur J Radiol 66 (2008) 208
18. Kalb R.E., Helm T.N., Sperry H., et al. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 158 (2008) 607
19. Perazella M.A. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link?. Clin J Am Soc Nephrol 2 (2007) 200
20. Shenoy C. Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney and liver disease. Am J Med 121 (2008) e11
21. Swaminathan S., Ahmed I., McCarthy J.T., et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145 (2006) 234
22. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148
23. Prince M.R., Zhang H., Morris M., et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248 (2008) 807
24. Deo A., Fogel M., and Cowper S.E. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2 (2007) 264
25. Broome D.R., Girguis M.S., Baron P.W., et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am Roentgenol 188 (2007) 586
26. Rydahl C., Thomsen H.S., and Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 43 (2008) 141
27. Edward M., Quinn J.A., Mukherjee S., et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 214 (2008) 584
28. Bucala R., Spegel L.A., Chesney J., et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1 (1994) 71
29. Bucala R. Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 5 (2008) 36
30. Sieber M.A., Pietsch H., Walter J., et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43 (2008) 65
31. Bosch E., Kreitner K.F., Peirano M.F., et al. Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study. AJR Am J Roentgenol 190 (2008) 179
32. Swaminathan S., and Shah S.V. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18 (2007) 2636
33. Cowper S.E., Rabach M., and Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66 (2008) 191
34. Chesney J., and Bucala R. Peripheral blood fibrocytes: mesenchymal precursor cells and the pathogenesis of fibrosis. Curr Rheumatol Rep 2 (2000) 501
35. Schroeder J.A., Weingart C., Coras B., et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 3 (2008) 968
36. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359
37. Gilliet M., Cozzio A., Burg G., et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152 (2005) 531-536
38. Othersen J.B., Maize J.C., Woolson R.F., et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22 (2007) 3179
39. Pieringer H., Schmekal B., Janko O., et al. Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 (2007) 3094
40. Introcaso C.E., Hivnor C., Cowper S., et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol 46 (2007) 447
41. Kay J., and High W.A. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 58 (2008) 2543
42. Saitoh T., Hayasaka K., Tanaka Y., et al. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24 (2006) 445
43. Food and Drug Administration Public Alert 06/2006, updated 12/2006 and 5/23/2007: GBC agents for magnetic resonance imaging Marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). http://www.fda.gov/cder/drug/InfoSheets/ 2007_05HCP.pdf Accessed April 8, 2008.
44. Kanal E., Barkovich A.J., Bell C., et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188 (2007) 1447
45. Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency?. MAGMA 20 (2007) 57
46. Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents. Dear Healthcare Professional Communication. MHRA Communication dated February 7, 2007. http://www.mhra.gov.uk/SearchHelp/Search/Searchresults/index.htm?within=Yes&keywords=gadolinium Accessed April 8, 2008.